Table 1 Summary of MNDA expression in B-cell non-Hodgkin lymphoma
MNDA expression | ||||||
|---|---|---|---|---|---|---|
Lymphomas | Kanellis G, et al. (15%) | Metcalf R, et al. (15%) | Wang Z, et al. (20%) | Kivrak H, et al. (15%) | Righi S, et al. (NA) | Li-Fen Z, et al. |
grade1-2: 3/69(4.3%) grade 3: 3/41(7.3%) | grade 1–2: 5/162(3.1%) | |||||
FL | 9/184(5%) | 3/14(21%) | 1/7(14%) | 0/79(0%) | grade 3: 7/65(10.8%) | |
Total:13/248(5.2%) | ||||||
NZML | 43/57(75%) | 16/24(66.7%) | 12/22(54%) | 11/14(78%) | 70/110(64%) | 62/94(66.0%) |
EMZL | 19/20(95%) | 27/44(61.4%) | 21/31(68%) | 11/17(64.7%) | 370/564(65.6%) | |
SMZL | 20/20(100%) | 5/21(23.8%) | 18/26(69%) | 38/55(69%) | 21/31(68%) | 5/5(100%) |
MCL | 61/74(82%) | 9/140(6.4%) | 7/9(78%) | NA | 27/61(44%,17BMB) | 82/103(79.6%) |
CLL/SLL | 23/35(65%) | 4/31(12.9%) | 8/15(53%) | 16/21(76%) | 24/87(28%,17BMB) | 26/58(44.8%) |
LPL | 10/12(83%) | 2/8(25%) | 3/8(37%) | 5/18(27.7%) | 3/10(30%) | 2/8(25.0%) |
DLBCL | 34/75(45%) | 2/61(3.3%) | NA | NA | NA | 63/213(29.6%) |
Total | 477 | 439 | 125 | 132 | 378 | 1293 |